10-Q Filing

TEVA PHARMACEUTICAL INDUSTRIES LTD CIK: 818686 Q2 2018

Filing Information

Form Type	10-Q
Accession Number	`0001193125-18-236536`
Period End Date	20180630
Filing Date	20180802
Fiscal Year	2018
Fiscal Period	Q2
XBRL Instance	teva-20180630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 87 Income Statement 95 Cash Flow Statement 68 Comprehensive Income 35

Balance Sheet 87 line items

Line Item	Tag	Value	Unit	Period
Preferred stock par or stated value per share	`PreferredStockParOrStatedValuePerShare`	$0.10	USD	Point-in-time
Preferred stock par or stated value per share	`PreferredStockParOrStatedValuePerShare`	$0.10	USD	Point-in-time
Preferred stock shares, authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock shares, authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$963.00M	USD	Point-in-time
Preferred stock shares, issued	`PreferredStockSharesIssued`	3.70M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.86B	USD	Point-in-time
Preferred stock shares, issued	`PreferredStockSharesIssued`	3.70M	shares	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$7.13B	USD	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	$0.10	USD	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$6.06B	USD	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	$0.10	USD	Point-in-time
Inventories	`InventoryNet`	$4.92B	USD	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Inventories	`InventoryNet`	$4.97B	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$1.10B	USD	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.12B	shares	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.12B	shares	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$1.10B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$685.00M	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	107.00M	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$701.00M	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	106.00M	shares	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$29.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$566.00M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$14.71B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$15.38B	USD	Point-in-time
Deferred income taxes	`DeferredTaxAssetsNetNoncurrent`	$574.00M	USD	Point-in-time
Deferred income taxes	`DeferredTaxAssetsNetNoncurrent`	$440.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$806.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$932.00M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$7.21B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$7.67B	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$16.21B	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$17.64B	USD	Point-in-time
Goodwill	`Goodwill`	$28.41B	USD	Point-in-time
Goodwill	`Goodwill`	$27.65B	USD	Point-in-time
Total assets	`Assets`	$67.03B	USD	Point-in-time
Total assets	`Assets`	$70.61B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$1.27B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$3.65B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$7.88B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$7.14B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.78B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$2.07B	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$549.00M	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$674.00M	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$3.01B	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$2.25B	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$1.10B	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$724.00M	USD	Point-in-time
Liabilities held for sale	`LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$38.00M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$17.92B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$14.21B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$3.28B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$2.67B	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.81B	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.84B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$28.96B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$28.83B	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$33.45B	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$33.95B	USD	Point-in-time
Commitments and contingencies, see note 16	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies, see note 16	`CommitmentsAndContingencies`	-	USD	Point-in-time
Total liabilities	`Liabilities`	$51.87B	USD	Point-in-time
Total liabilities	`Liabilities`	$47.66B	USD	Point-in-time
Preferred shares of NIS 0.10 par value per mandatory convertible preferred share; June 30, 2018 and December 31, 2017: authorized 5.0 million shares; issued 3.7 million shares	`PreferredStockValue`	$3.63B	USD	Point-in-time
Preferred shares of NIS 0.10 par value per mandatory convertible preferred share; June 30, 2018 and December 31, 2017: authorized 5.0 million shares; issued 3.7 million shares	`PreferredStockValue`	$3.76B	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; June 30, 2018 and December 31, 2017: authorized 2,495 million shares; issued 1,124 million shares	`CommonStockValue`	$54.00M	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; June 30, 2018 and December 31, 2017: authorized 2,495 million shares; issued 1,124 million shares	`CommonStockValue`	$54.00M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$23.43B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$23.48B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-2.86B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-3.81B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-1.85B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.29B	USD	Point-in-time
Treasury shares as of June 30, 2018 and December 31, 2017 - 106 million ordinary shares and 107 million ordinary shares, respectively	`TreasuryStockValue`	$4.15B	USD	Point-in-time
Treasury shares as of June 30, 2018 and December 31, 2017 - 106 million ordinary shares and 107 million ordinary shares, respectively	`TreasuryStockValue`	$4.15B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$17.94B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$17.36B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.43B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.39B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.75B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.37B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$67.03B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$70.61B	USD	Point-in-time

Income Statement 95 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`RevenueFromContractWithCustomerIncludingAssessedTax`	$11.37B	USD	2 Qtrs
Net revenues	`RevenueFromContractWithCustomerIncludingAssessedTax`	$4.70B	USD	1 Quarter
Net revenues	`RevenueFromContractWithCustomerIncludingAssessedTax`	$5.72B	USD	1 Quarter
Net revenues	`RevenueFromContractWithCustomerIncludingAssessedTax`	$9.77B	USD	2 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$2.87B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$2.64B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$5.36B	USD	2 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$5.68B	USD	2 Qtrs
Gross profit	`GrossProfit`	$2.06B	USD	1 Quarter
Gross profit	`GrossProfit`	$2.85B	USD	1 Quarter
Gross profit	`GrossProfit`	$5.69B	USD	2 Qtrs
Gross profit	`GrossProfit`	$4.41B	USD	2 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$469.00M	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$901.00M	USD	2 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$290.00M	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$607.00M	USD	2 Qtrs
Selling and marketing expenses	`SellingAndMarketingExpense`	$944.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$1.48B	USD	2 Qtrs
Selling and marketing expenses	`SellingAndMarketingExpense`	$1.90B	USD	2 Qtrs
Selling and marketing expenses	`SellingAndMarketingExpense`	$710.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$729.00M	USD	2 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$316.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$363.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$645.00M	USD	2 Qtrs
Other asset impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$419.00M	USD	1 Quarter
Other asset impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$715.00M	USD	1 Quarter
Other asset impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$659.00M	USD	2 Qtrs
Other asset impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$1.42B	USD	2 Qtrs
Goodwill impairment	`GoodwillImpairmentLoss`	$6.10B	USD	1 Quarter
Goodwill impairment	`GoodwillImpairmentLoss`	$300.00M	USD	2 Qtrs
Goodwill impairment	`GoodwillImpairmentLoss`	$120.00M	USD	1 Quarter
Goodwill impairment	`GoodwillImpairmentLoss`	$6.10B	USD	2 Qtrs
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$344.00M	USD	2 Qtrs
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$324.00M	USD	1 Quarter
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$-1.26B	USD	2 Qtrs
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$20.00M	USD	1 Quarter
Other income	`OtherIncome`	$96.00M	USD	2 Qtrs
Other income	`OtherIncome`	$24.00M	USD	1 Quarter
Other income	`OtherIncome`	$96.00M	USD	1 Quarter
Other income	`OtherIncome`	$299.00M	USD	2 Qtrs
Operating income (loss)	`OperatingIncomeLoss`	$-4.84B	USD	2 Qtrs
Operating income (loss)	`OperatingIncomeLoss`	$-14.00M	USD	1 Quarter
Operating income (loss)	`OperatingIncomeLoss`	$1.51B	USD	2 Qtrs
Operating income (loss)	`OperatingIncomeLoss`	$-5.74B	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-238.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-507.00M	USD	2 Qtrs
Financial expenses, net	`NonoperatingIncomeExpense`	$-236.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-445.00M	USD	2 Qtrs
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-250.00M	USD	1 Quarter
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-5.29B	USD	2 Qtrs
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$1.00B	USD	2 Qtrs
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-5.98B	USD	1 Quarter
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$-22.00M	USD	1 Quarter
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$32.00M	USD	2 Qtrs
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$-30.00M	USD	2 Qtrs
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$-76.00M	USD	1 Quarter
Share in (profits) losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$-66.00M	USD	2 Qtrs
Share in (profits) losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$-14.00M	USD	1 Quarter
Share in (profits) losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$8.00M	USD	1 Quarter
Share in (profits) losses of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$-7.00M	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$-5.33B	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$-5.97B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$968.00M	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$-166.00M	USD	1 Quarter
Net Income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-4.00M	USD	2 Qtrs
Net Income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$10.00M	USD	1 Quarter
Net Income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$24.00M	USD	2 Qtrs
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-176.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-5.97B	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-5.33B	USD	2 Qtrs
Net income (loss) attributable to Teva	`NetIncomeLoss`	$944.00M	USD	2 Qtrs
Dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$130.00M	USD	2 Qtrs
Dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$65.00M	USD	1 Quarter
Dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$65.00M	USD	1 Quarter
Dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$130.00M	USD	2 Qtrs
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-6.04B	USD	1 Quarter
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-5.46B	USD	2 Qtrs
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-241.00M	USD	1 Quarter
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$814.00M	USD	2 Qtrs
Basic	`EarningsPerShareBasic`	$-5.37	USD	2 Qtrs
Basic	`EarningsPerShareBasic`	$0.80	USD	2 Qtrs
Basic	`EarningsPerShareBasic`	$-0.24	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$-5.94	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-5.94	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-5.37	USD	2 Qtrs
Diluted	`EarningsPerShareDiluted`	$-0.24	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.80	USD	2 Qtrs
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.02B	shares	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.02B	shares	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.02B	shares	2 Qtrs
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.02B	shares	2 Qtrs
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.02B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.02B	shares	2 Qtrs
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.02B	shares	2 Qtrs
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.02B	shares	1 Quarter

Cash Flow Statement 68 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$-5.33B	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$-5.97B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$968.00M	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$-166.00M	USD	1 Quarter
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$1.35B	USD	2 Qtrs
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$1.27B	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$1.06B	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$986.00M	USD	2 Qtrs
Impairment of long-lived assets	`AssetImpairmentCharges`	$159.00M	USD	2 Qtrs
Impairment of long-lived assets	`AssetImpairmentCharges`	$980.00M	USD	2 Qtrs
Deferred income taxes - net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-127.00M	USD	2 Qtrs
Deferred income taxes - net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-489.00M	USD	2 Qtrs
Goodwill impairment	`GoodwillImpairmentLoss`	$6.10B	USD	1 Quarter
Goodwill impairment	`GoodwillImpairmentLoss`	$300.00M	USD	2 Qtrs
Goodwill impairment	`GoodwillImpairmentLoss`	$120.00M	USD	1 Quarter
Goodwill impairment	`GoodwillImpairmentLoss`	$6.10B	USD	2 Qtrs
Impairment of equity investment	`ImpairmentOfInvestments`	$94.00M	USD	2 Qtrs
Net gain from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$65.00M	USD	2 Qtrs
Net gain from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$88.00M	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$75.00M	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$77.00M	USD	2 Qtrs
Research and development in process	`ResearchAndDevelopmentExpense`	$54.00M	USD	2 Qtrs
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$-44.00M	USD	2 Qtrs
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$-34.00M	USD	2 Qtrs
Venezuela impairment of net monetary assets	`VenezuelaImpairmentOfNetMonetaryAssets`	$18.00M	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.66B	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$571.00M	USD	2 Qtrs
Beneficial interest collected in exchanged for securitized trade receivables	`CashFlowsBetweenTransferorAndTransfereeBeneficialInterest`	$970.00M	USD	2 Qtrs
Beneficial interest collected in exchanged for securitized trade receivables	`CashFlowsBetweenTransferorAndTransfereeBeneficialInterest`	$640.00M	USD	2 Qtrs
Proceeds from sales of business, investments and long-lived assets	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$841.00M	USD	2 Qtrs
Proceeds from sales of business, investments and long-lived assets	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$1.49B	USD	2 Qtrs
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$395.00M	USD	2 Qtrs
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$299.00M	USD	2 Qtrs
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$56.00M	USD	2 Qtrs
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$14.00M	USD	2 Qtrs
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$11.00M	USD	2 Qtrs
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$286.00M	USD	2 Qtrs
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$1.43B	USD	2 Qtrs
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$1.45B	USD	2 Qtrs
Repayment of long-term loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$6.29B	USD	2 Qtrs
Repayment of long-term loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$583.00M	USD	2 Qtrs
Proceeds from long-term loans, net of issuance costs	`ProceedsFromIssuanceOfLongTermDebt`	$521.00M	USD	2 Qtrs
Proceeds from long-term loans, net of issuance costs	`ProceedsFromIssuanceOfLongTermDebt`	$4.43B	USD	2 Qtrs
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$-1.48B	USD	2 Qtrs
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$-261.00M	USD	2 Qtrs
Dividends paid on ordinary shares	`PaymentsOfDividendsCommonStock`	$12.00M	USD	2 Qtrs
Dividends paid on ordinary shares	`PaymentsOfDividendsCommonStock`	$691.00M	USD	2 Qtrs
Dividends paid on preferred shares	`PaymentsOfDividendsPreferredStockAndPreferenceStock`	$10.00M	USD	2 Qtrs
Dividends paid on preferred shares	`PaymentsOfDividendsPreferredStockAndPreferenceStock`	$130.00M	USD	2 Qtrs
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-10.00M	USD	2 Qtrs
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-21.00M	USD	2 Qtrs
Dividends paid to non-controlling interests	`PaymentsOfDividendsMinorityInterest`	$38.00M	USD	2 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.42B	USD	2 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.15B	USD	2 Qtrs
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-58.00M	USD	2 Qtrs
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$29.00M	USD	2 Qtrs
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-389.00M	USD	2 Qtrs
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$898.00M	USD	2 Qtrs
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.86B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$599.00M	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$963.00M	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$988.00M	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.86B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$599.00M	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$963.00M	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$988.00M	USD	Point-in-time
Beneficial interest obtained in exchange for securitized trade receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$591.00M	USD	Point-in-time
Beneficial interest obtained in exchange for securitized trade receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$968.00M	USD	Point-in-time

Comprehensive Income 35 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$-5.33B	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$-5.97B	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$968.00M	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$-166.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-711.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$406.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-472.00M	USD	2 Qtrs
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$872.00M	USD	2 Qtrs
Unrealized gain (loss) from derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-100.00M	USD	1 Quarter
Unrealized gain (loss) from derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-56.00M	USD	2 Qtrs
Unrealized gain (loss) from derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$77.00M	USD	1 Quarter
Unrealized gain (loss) from derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$69.00M	USD	2 Qtrs
Unrealized gain (loss) from available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-1.00M	USD	2 Qtrs
Unrealized gain (loss) from available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-1.00M	USD	1 Quarter
Unrealized gain (loss) from available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-17.00M	USD	1 Quarter
Unrealized gain (loss) from available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$37.00M	USD	2 Qtrs
Unrealized loss on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-13.00M	USD	2 Qtrs
Unrealized loss on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-2.00M	USD	1 Quarter
Unrealized loss on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-1.00M	USD	2 Qtrs
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$312.00M	USD	1 Quarter
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-418.00M	USD	2 Qtrs
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$827.00M	USD	2 Qtrs
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-614.00M	USD	1 Quarter
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-4.50B	USD	2 Qtrs
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$550.00M	USD	2 Qtrs
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-780.00M	USD	1 Quarter
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-5.66B	USD	1 Quarter
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$46.00M	USD	2 Qtrs
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$64.00M	USD	2 Qtrs
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-2.00M	USD	1 Quarter
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-51.00M	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$504.00M	USD	2 Qtrs
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-4.57B	USD	2 Qtrs
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-5.66B	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-729.00M	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.